Suppr超能文献

通过调节泛素蛋白酶体系统来控制细胞内蛋白质水平的小分子。

Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system.

机构信息

Departments of Chemistry; Molecular, Cellular and Developmental Biology; and Pharmacology, Yale University, New Haven, CT 06511 (USA).

出版信息

Angew Chem Int Ed Engl. 2014 Feb 24;53(9):2312-30. doi: 10.1002/anie.201307761. Epub 2014 Jan 23.

Abstract

Traditionally, biological probes and drugs have targeted the activities of proteins (such as enzymes and receptors) that can be readily controlled by small molecules. The remaining majority of the proteome has been deemed "undruggable". By using small-molecule modulators of the ubiquitin proteasome, protein levels, rather than protein activity, can be targeted instead, thus increasing the number of druggable targets. Whereas targeting of the proteasome itself can lead to a global increase in protein levels, the targeting of other components of the UPS (e.g., the E3 ubiquitin ligases) can lead to an increase in protein levels in a more targeted fashion. Alternatively, multiple strategies for inducing protein degradation with small-molecule probes are emerging. With the ability to induce and inhibit the degradation of targeted proteins, small-molecule modulators of the UPS have the potential to significantly expand the druggable portion of the proteome beyond traditional targets, such as enzymes and receptors.

摘要

传统上,生物探针和药物针对的是蛋白质(如酶和受体)的活性,这些活性可以通过小分子很容易地控制。剩下的大多数蛋白质组被认为是“不可成药的”。通过使用泛素蛋白酶体的小分子调节剂,可以靶向蛋白质水平,而不是蛋白质活性,从而增加可成药的靶标数量。虽然靶向蛋白酶体本身会导致蛋白质水平的全面增加,但靶向 UPS 的其他成分(例如,E3 泛素连接酶)可以更有针对性地增加蛋白质水平。或者,用小分子探针诱导蛋白质降解的多种策略正在出现。具有诱导和抑制靶向蛋白降解的能力,泛素蛋白酶体的小分子调节剂有可能显著扩大蛋白质组的可成药部分,超越传统的靶标,如酶和受体。

相似文献

3
The Small Molecules Targeting Ubiquitin-Proteasome System for Cancer Therapy.靶向泛素-蛋白酶体系统用于癌症治疗的小分子
Comb Chem High Throughput Screen. 2017;20(5):403-413. doi: 10.2174/1386207320666170710124746.
6
Targeted protein degradation and the enzymology of degraders.靶向蛋白降解与降解剂的酶学。
Curr Opin Chem Biol. 2018 Jun;44:47-55. doi: 10.1016/j.cbpa.2018.05.004. Epub 2018 Jun 7.
8
Perspectives on the development of first-in-class protein degraders.对首创蛋白降解剂开发的看法。
Future Med Chem. 2021 Jul;13(14):1203-1226. doi: 10.4155/fmc-2021-0033. Epub 2021 May 21.
9
Proteasome substrate receptors and their therapeutic potential.蛋白酶体底物受体及其治疗潜力。
Trends Biochem Sci. 2022 Nov;47(11):950-964. doi: 10.1016/j.tibs.2022.06.006. Epub 2022 Jul 9.

引用本文的文献

10
Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope.非小分子PROTAC(NSM-PROTAC):蛋白质降解万花筒
Acta Pharm Sin B. 2022 Jul;12(7):2990-3005. doi: 10.1016/j.apsb.2022.02.022. Epub 2022 Feb 26.

本文引用的文献

10
Synthesis and pharmacology of proteasome inhibitors.蛋白酶体抑制剂的合成与药理学。
Angew Chem Int Ed Engl. 2013 May 17;52(21):5450-88. doi: 10.1002/anie.201207900. Epub 2013 Mar 25.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验